Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

880

Participants

Timeline

Start Date

October 15, 2015

Primary Completion Date

October 7, 2026

Study Completion Date

October 7, 2026

Conditions
Atopic Dermatitis
Interventions
DRUG

Dupilumab

Weight-tiered dosing administered subcutaneous (SC)

Trial Locations (84)

3526

Regeneron Investigational Site, Miskolc

5000

Regeneron Investigational Site, Szolnok

6720

Regeneron Investigational Site, Szeged

7400

Regeneron Investigational Site, Kaposvár

10029

Regeneron Investigational Site, New York

10034

Regeneron Investigational Site, Prague

11375

Regeneron Investigational Site, Forest Hills

14642

Regeneron Investigational Site, Rochester

19104

Regeneron Investigational site, Philadelphia

20016

Regeneron Investigational Site, Washington D.C.

20850

Regeneron Investigational Site, Rockville

22149

Regeneron Investigational Site, Hamburg

23502

Regeneron Investigational Site, Norfolk

28401

Regeneron Investigational Site, Kutná Hora

29420

Regeneron Investigational Site, North Charleston

29425

Regeneron Investigational Site, Charleston

30328

Regeneron Investigational Site, Sandy Springs

31217

Regeneron Investigational Site, Macon

31904

Regeneron Investigational Site, Columbus

33146

Regeneron Investigational Site, Coral Gables

33613

Regeneron Investigational Site, Tampa

33624

Regeneron Investigational Site, Tampa

35209

Regeneron Investigational Site, Birmingham

40113

Regeneron Investigational Site, Ústí nad Labem

43230

Regeneron Investigational Site, Gahanna

46168

Regeneron Investigational site, Plainfield

48149

Regeneron Investigational Site, Münster

48197

Regeneron Investigational Site, Ypsilanti

50368

Regeneron Investigational Site, Wroclaw

55441

Regeneron Investigational Site, Plymouth

60077

Regeneron Investigational Site, Skokie

60590

Regeneron Investigational Site, Frankfurt am Main

60611

Regeneron Investigational Site, Chicago

63104

Regeneron Investigational Site, St Louis

72076

Regeneron Study Site, Tübingen

76244

Regeneron Investigational Site, Fort Worth

78218

Regeneron Investigational Site, San Antonio

80112

Regeneron Investigational Site, Centennial

80337

Regeneron Investigational Site, Munich

80802

Regeneron Study Site, München

85234

Regeneron Investigational Site, Gilbert

90027

Regeneron Investigational Site, Los Angeles

90274

Regeneron Investigational Site, Rolling Hills Estates

90808

Regeneron Investigational Site, Long Beach

92123

Regeneron Investigational Site, San Diego

92304

Regeneron Investigational Site, Palo Alto

92691

Regeneron Investigational site, Mission Viejo

92868

Regeneron Investigational Site, Orange

93309

Regeneron Investigational Site, Bakersfield

97239

Regeneron Investigational Site, Portland

98105

Regeneron Investigational Site, Seattle

02115

Regeneron Investigational Site, Boston

02116

Regeneron Investigational Site, Boston

77401-3505

Regeneron Investigational Site, Bellaire

T2G 1B1

Regeneron Investigational Site, Calgary

V3R 6A7

Regeneron Investigational Site, Surrey

R3C 0N2

Regeneron Investigational Site, Winnipeg

L3P 1X2

Regeneron Investigational Site, Markham

K2C 2N3

Regeneron Investigational Site, Ottawa

K9J 5K2

Regeneron Investigational Site, Peterborough

N2J 1C4

Regeneron Investigational Site, Waterloo

N8W 1E6

Regeneron Investigational Site, Windsor

H3T 1C5

Regeneron Investigational Site, Montreal

01307

Regeneron Investigational Site, Dresden

07548

Regeneron Investigational Site, Gera

27-400

Regeneron Investigational Site, Ostrowiec Świętokrzyski

50-381

Regeneron Investigational Site, Wroclaw

30 363

Regeneron Investigational Site, Krakow

Regeneron Investigational Site, Krakow

31-011

Regeneron Investigational Site, Krakow

40-648

Regeneron Investigational Site, Katowice

15 453

Regeneron Investigational Site, Bialystok

85-065

Regeneron Investigational Site, Bydgoszcz

41-500

Regeneron Investigational Site, Chorzów

80-152

Regeneron Investigational Site, Gdansk

40 611

Regeneron Investigational Site, Katowice

90-265

Regeneron Investigational Site, Lodz

01-142

Regeneron Investigational Site, Warsaw

01-817

Regeneron Investigational Site, Warsaw

02-758

Regeneron Investigational Site, Warsaw

91-142

Regeneron Investigational Site, Warsaw

SE1 7EH

Regeneron Investigational Site, London

M13 9WL

Regeneron Investigational Site, Manchester

S10 2TH

Regeneron Investigational Site, Sheffield

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT02612454 - Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) | Biotech Hunter | Biotech Hunter